42. The kit according to claim 41, further comprising (a) a growth factor selected from the group consisting of fibroblast growth factor 2 (FGF2), epidermal growth factor (EGF), hepatocyte growth factor (HGF) and keratinocyte growth factor (KGF); and/or (b) a conditioned medium such as a conditioned medium from a rat insulinoma (Rin5f) cell line; and/or (c) a medium selected from B-27® supplement (comprising BSA, transferrin, insulin, progesterone, putrescine, sodium selenite, biotin, l-carnitine, corticosterone, ethanolamine, d(+)-galactose, glutathione (reduced), linolenic acid, linoleic acid, retinyl acetate, selenium, t3 (triodo-1-thyronine), dl-α-tocopherol (vitamine e), dl-α-tocopherol acetate, catalase, superoxide dismutase) and TeSR™2 (comprising DMEM/F12 (liquid), L-ascorbic Acid, selenium, transferrin, NaHCO3, glutathione, L-glutamine, defined lipids, thiamine, ß-mercaptoethanol, albumin, insulin, FGF2, TGFß1, pipecolic acid, LiCl, GABA); and

a scaffold for supporting growth of the cells being reprogrammed, wherein optionally, said scaffold comprises a nanotopographical scaffold, and wherein optionally said nanotopographical scaffold comprises uniform arrays of silica nanoparticles.

43. A reprogrammed cell obtained according to the method of any one of claims 1 to 39 for use in treating a patient in need of cell-based therapy or tissue replacement, wherein said reprogrammed cell is to be administered to said patient.

44. Use of a reprogrammed cell obtained according to the method of any one of claims 1 to 39 in the manufacture of a medicament for treating a patient in need of cell-based therapy or tissue replacement, wherein said medicament is to be administered to said patient.

45. A bioactive comprising as a vehicle, a reprogrammed cell obtained according to the method of any one of claims 1 to 39, for use in treating a patient in need of cancer therapy.

46. Use of a bioactive comprising as a vehicle, a reprogrammed cell obtained according to the method of any one of claims 1 to 39, in the manufacture of a medicament for treating a patient in need of cancer therapy.

47. An *in vitro* method of determining the suitability of a cancer therapy for a cancer patient, comprising preparing a reprogrammed cell according to the method of any one of

claims 1 to 39, and administering to said reprogrammed cell one or more cancer therapy to assess efficacy of said cancer therapy on said reprogrammed cell.

48. The reprogrammed cell of claim 43, the bioactive of claim 45, the use of claim 44 or 46, or the method of claim 47, wherein the reprogrammed cell is one that is derived from the patient.